We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Survival of stage IV melanoma in Belgium and the Netherlands.
- Authors
Suijkerbuijk, K.P.M.; Haanen, J.B.A.G.; Boers‐Sonderen, M.J.; Hospers, G.A.P.; Blank, C.U.; van den Berkmortel, F.W.P.J.; de Groot, J.W.B.; Piersma, D.; Aarts, M.J.B.; van Rijn, R.S.; Vreugdenhil, G.; Westgeest, H.M.; Kapiteijn, E.; van der Veldt, A.A.M.; van den Eertwegh, A.J.M.
- Abstract
Dr Aarts has advisory board / consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Prof vd Eertwegh has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis. Dr Suijkerbuijk has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, Abbvie and received honoraria from Novartis, MSD and Roche.
- Subjects
NETHERLANDS; BELGIUM; MELANOMA; RESEARCH grants; TRAVEL costs
- Publication
Journal of the European Academy of Dermatology & Venereology, 2022, Vol 36, Issue 2, pe118
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.17668